Información del artículo
El Texto completo está disponible en PDF
Biblografía
[1.]
P.R. Shepherd, S.K. Kahn.
Glucose transporters and insulin action.
N Engl J Med, 341 (1999), pp. 248-257
[2.]
J.C. Pickup, G. Williams.
Insulin resistance in non-insulin-dependent diabetes mellitus. Textbook of diabetes.
[3.]
E. Faure, E. Esteve.
Hiperinsulinemia y resistencia a la insulina.
Diabetes mellitus tipo 2 y factores de riesgo cardiovascular, pp. p79-p102
[4.]
E.A. McIntyre, M. Walter.
Genetics of type 2 diabetes and insulin resistance: knowledge from human studies.
Clin Endocrinol (Oxf), 57 (2002), pp. 303-311
[5.]
G. Roden.
Pathogenesis of type 2 diabetes. Insulin resistance.
Endocrinol Metab Clin North Am, 30 (2001), pp. 801-815
[6.]
K.G. Alberti, P.Z. Zimmet.
Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation.
Diabet Med, 15 (1998), pp. 539-553
[7.]
C. Megyesi, E. Samols, V. Marks.
Glucose tolerance and diabetes in chronic liver disease.
Lancet, 2 (1967), pp. 1051-1056
[8.]
H.O. Conn, W. Schreiber, S.G. Elkington, T.R. Johnson.
Cirrhosis and diabetes. Increased incidence of diabetes in patients with Laennec's cirrhosis. I.
Am J Dig Dis, 14 (1969), pp. 837-852
[9.]
H.O. Conn, W. Schreiber, S.G. Elkington.
Cirrhosis and diabetes. Association of impaired glucose tolerance with portal-systemic shunting in Laennec's cirrhosis.
Am J Dig Dis, 16 (1971), pp. 227-239
[10.]
S. Gentile, C. Loguercio, R. Marmo, L. Carbone, C. Del Vecchio-Blanco.
Incidence of altered glucose tolerance in liver cirrhosis.
Diabetes Res Clin Pract, 22 (1993), pp. 37-44
[11.]
B. Naunyn.
Der Diabetes Mellitus Nothnagels handbuch.
[12.]
D.G. Johnston, K.G.M.M. Alberti, O.K. Baber, C. Binder, R. Wright.
Hyperinsulinism of hepatic cirrhosis: diminished degradation or hypersecretion?.
Lancet, i (1977), pp. 10-13
[13.]
A.S. Petrides, R.A. De Fronzo.
Glucose metabolism in cirrhosis: a review with some perspectives for the future.
Diabetes Metab Rev, 5 (1989), pp. 691-709
[14.]
A.S. Petrides, L.C. Groop, C.A. Riely, R.A. De Fronzo.
Effect of physiologic hyperinsulinemia on glucose and lipid metabolism in cirrhosis.
J Clin Invest, 88 (1991), pp. 561-570
[15.]
O. Selberg, BurchertW, J. Van der Hoff, G.J. Meyer, H. Hundeshagen, E. Radoch, et al.
Insulin resistance in liver cirrhosis. Positron-emission tomography scan analysis of skeletal muscle glucose metabolism.
J Clin Invest, 91 (1993), pp. 1897-1902
[16.]
A.S. Petrides.
Liver disease and diabetes mellitus.
Diabetes Rev, 2 (1994), pp. 2-18
[17.]
A.S. Petrides, T. Stanley, D.E. Matthews, C. Vogt, A.J. Bush, H. Lambeth.
Insulin resistance in cirrhosis: prolonged reduction of hyperinsulinemia normalizes insulin sensitivity.
Hepatology, 28 (1998), pp. 141-149
[18.]
A.S. Petrides, C. Vogt, D. Schulze-Berge, D. Matthews, G. Strohmeyer.
Pathogenesis of glucose intolerance and diabetes mellitus in cirrhosis.
Hepatology, 19 (1994), pp. 616-627
[19.]
Y. Kruszynska, P.D. Home, N. McIntyre.
Relationship between insulin insensitivity, insulin secretion and glucose tolerance in cirrhosis.
Hepatology, 14 (1991), pp. 103-111
[20.]
G. Perseghin, V. Mazzaferro, L.P. Sereni, E. Regalia, S. Benedini, E. Bazzigaluppi, et al.
Contribution of reduced insulin sensitivity and secretion to the pathogenesis of hepatogenous diabetes: effect of liver transplantation.
Hepatology, 31 (2000), pp. 694-703
[21.]
P. Angulo.
Non alcoholic fatty liver disease.
N Engl J Med, 346 (2002), pp. 1221-1231
[22.]
AGA.
Technical review on nonalcoholic fatty liver disease [editorial].
Gastroenterology, 123 (2002), pp. 1705-1725
[23.]
E.M. Brunt.
Nonalcoholic steatohepatitis: definition and pathology.
Semin Liv Dis, 21 (2001), pp. 3-16
[24.]
A.J. McCullough.
Insulin resistances, obesity and fatty liver disease. Syllabus of Postgraduate Course 2002: mechanisms of acute & chronic liver diseases: implications for diagnosis, pathogenesis and treatment.
pp. p134-p143
[25.]
A.J. Sanyal, C. Campbell-Sargent, F. Mirshahi, et al.
Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities.
Gastroenterology, 120 (2001), pp. 1183-1192
[26.]
S. Chitturi, S. Abeygunasekera, G.C. Farell, J. Holmes-Walker, J. Hui, C. Fung, et al.
NASH and insulin resistance: insulin secretion and specific association with the insulin resistance syndrome.
Hepatology, 35 (2002), pp. 373-379
[27.]
G. Marchesini, M. Brizi, A. Morselli-Labate, G. Bianchi, E. Bugianesi, A.J. McCullough, et al.
Association of nonalcohollic fatty liver disease with insulin resistance.
Am J Med, 107 (1999), pp. 450-455
[28.]
G. Pagano, G. Pacini, G. Musso, R. Gambino, F. Mecca, N. Depetris, M. Cassader, et al.
Nonalcoholic steatohepatitis, insulin resistance and metabolic syndrome: further evidence for an etiological association.
Hepatology, 35 (2002), pp. 367-372
[29.]
G. Marchesini, M. Brizi, G. Bianchi, et al.
Non-alcoholic fatty liver disease. A feature of the metabolic syndrome.
Diabetes, 50 (2001), pp. 1844-1850
[30.]
A.R. Saltiel.
New perspectives into the molecular pathogenesis and treatment of type 2 diabetes.
Cell, 104 (2001), pp. 517-529
[31.]
D.L. Rothman, I. Magnusson, L.D. Katz, R.G. Shulman, G.I. Shulman.
Quantitation of hepatic glycogenolysis and gluconeogenesis in fasting humans with 13C NMR.
Science, 254 (1991), pp. 573-576
[32.]
I. Magnusson, D.L. Rothman, L.D. Katz, R.G. Shulman, G.I. Shulman.
Increased rate of gluconeogenesis in type II diabetes mellitus. A 13C nuclear magnetic resonance study.
J Clin Invest, 90 (1992), pp. 1323-1327
[33.]
B.A. Neuchswander, S.H. Caldwell.
Nonalcoholic steatohepatitis: summary of an AASLD single topic conference.
Hepatology, 37 (2003), pp. 1202-1219
[34.]
K.T. Uysal, S.M. Wiesbrock, M.W. Marino, G.S. Hotamisligil.
Protection from obesity-induced insulin resistance in mice lacking TNF-α function.
Nature, 389 (1997), pp. 610-614
[35.]
N. Barzilai, J. Wang, D. Massilon, P. Vuguin, M. Hawkins, L. Rossetti.
Leptin selectively decreases visceral adiposity and enhances insulin action.
J Clin Invest, 100 (1997), pp. 3105-3110
[36.]
C.M. Steppan, S.T. Bailey, S. Bhat, E.J. Brown, R.R. Banerjee, C.M. Wright, et al.
The hormone resistin links obesity to diabetes.
Nature, 409 (2001), pp. 307-312
[37.]
M. Kondo, I. Shimomura, Y. Matsukawa, K. Kumada, M. Takahashi, M. Matsuda, et al.
Association of adiponectin mutation with type 2 diabetes: a candidate gene for the insulin resistance syndrome.
Diabetes, 51 (2002), pp. 2325-2328
[38.]
A.R. Shuldiner, R. Yang, D.W. Gong.
Resistin, obesity and insulin resistance: the emerging role of adipocyte as an endocrine organ.
N Engl J Med, 345 (2001), pp. 1345-1346
[39.]
J.G. Kral, F. Schaffner, R.N. Pierson Jr, J. Wang.
Body fat topography as an independent predictor of fatty liver.
Metabolism, 42 (1993), pp. 548-551
[40.]
M.D. Weltman, G.C. Farrell, P. Hall, M. Ingelman-Sundberg, C. Liddle.
Hepatic cytochrome P-450 2E1 is increased in patients with nonalcoholic steatohepatitis.
Hepatology, 27 (1998), pp. 128-133
[41.]
C.P. Day, O.F.W. James.
Steatohepatitis: a tale of two «hits»?.
Gastroenterology, 114 (1998), pp. 842-845
[42.]
D. Pessayre, A. Berson, B. Fromenty, A. Mansouri.
Mitocondria in steatohepatitis.
Semin Liv Dis, 21 (2001), pp. 57-69
[43.]
C.P. Day.
Non-alcoholic steatohepatitis (NASH): where are we now and where are we going?.
Gut, 50 (2002), pp. 585-588
[44.]
I.A. Leclercq, G.C. Farrell, J. Field, et al.
CYP2E1 y CYP4A as microsomal catalyst of lipid peroxides in murine non-alcoholic steatohepatitis.
J Clin Invest, 105 (2000), pp. 1067-1075
[45.]
D.K. George, S. Goldwurm, G.A. Macdonald, et al.
Increased hepatic iron concentration in non-alcoholic steatohepatitis is associated with increased fibrosis.
Gastroenterology, 114 (1998), pp. 311-318
[46.]
G. Marchesini, M. Brizi, G. Bianchi, S. Tomassetti, M. Zoli, N. Melchionda.
Metformin in nonalcoholic steatohepatitis.
Lancet, 358 (2001), pp. 893-894
[47.]
S.H. Caldwell, E.E. Hespenheide, J.A. Redick, J.C. Iezzoni, E.H. Battle, B.L. Sheppard.
A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis.
Am J Gastroenterol, 96 (2001), pp. 519-525
[48.]
B.A. Neuschwander-Tetri, E.M. Brunt, B.R. Bacon, C. Sponseller, K.R. Wehmeier, K. Hampton.
Histological improvement in NASH following increased insulin sensitivity with the PPAR-ã agonistrosiglitazone for 48 weeks [abstract].
Hepatology, 36 (2002), pp. A379
[49.]
T. Azuma, K. Tomita, S. Kato, M. Adachi, N. Inokuchi, N. Kitamura, et al.
A pilot study of a thiazolidinedione, pioglitazone, in nonalcoholic steatohepatitis [abstract].
Hepatology, 36 (2002), pp. A406
[50.]
A.J. Sanyal, M.J. Contos, C. Sargeant, R.T. Stravitz, V.A. Luketic, R.K. Sterling, et al.
A randomized controlled pilot study of pioglitazone and vitamin E versus vitamin E for non-alcoholic steatohepatitis [abstract].
Hepatology, 36 (2002), pp. A382
[51.]
K. Promrat, G. Lutchman, G.I. Uwaifo, R.J. Freedman, A. Soza, T. Heller, et al.
A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis.
Hepatology, 39 (2004), pp. 188-196
Copyright © 2004. Elsevier España, S.L.. Todos los derechos reservados
